Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

1
15
0

Year Published

2018
2018
2020
2020

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 22 publications
(16 citation statements)
references
References 5 publications
(9 reference statements)
1
15
0
Order By: Relevance
“…In the current analysis, patients who discontinued treatment because of any sTRAE had survival rates that were comparable to the overall population. Some preclinical and clinical evidence suggests that concomitant treatment with corticosteroids to manage immune‐related AEs may compromise the antitumor response . In this analysis, similar efficacy was achieved in patients with and without sTRAEs, as ORRs were comparable in both groups.…”
Section: Discussionsupporting
confidence: 52%
“…In the current analysis, patients who discontinued treatment because of any sTRAE had survival rates that were comparable to the overall population. Some preclinical and clinical evidence suggests that concomitant treatment with corticosteroids to manage immune‐related AEs may compromise the antitumor response . In this analysis, similar efficacy was achieved in patients with and without sTRAEs, as ORRs were comparable in both groups.…”
Section: Discussionsupporting
confidence: 52%
“…In contrast to the frequent early use of dexamethasone for tumor-associated edema, corticosteroid use for immunotherapy-related toxicity is always given after treatment has commenced. Corticosteroids have been established as causing dose-related immunosuppression, yet the mechanisms behind this impaired immune function, particularly in the context of cancer immunotherapy, have not been defined [ 38 ]. Importantly, it is not known if corticosteroids impede the differentiation of freshly stimulated T cells or if they deplete established and already differentiated tumor-reactive lymphocytes.…”
Section: Discussionmentioning
confidence: 99%
“…As a promising anti-tumor treatment, immunotherapy enhances the innate immune response by regulation of immune checkpoints [8]. However, it is associated with a number of immune-associated adverse effects such as autoimmune disorders [9]. Adjuvant treatment with high-dose DEX is an effective way to combat the side effects of immunotherapy [10].…”
Section: Introductionmentioning
confidence: 99%
“…(A) Schematic of the DEX treatment schedule. Mice were inoculated subcutaneously with 5 × 10 5 Lewis lung carcinoma (LLC) cells, and on days 7,9,11,13,15,17,19, and 21 post-inoculation, mice were intraperitoneally treated with 0.9% NaCl or various doses of DEX (2 mg/kg, 10 mg/kg, and 50 mg/kg). (B) Representative tumor growth in mice treated with 0.9% NaCl or various doses of DEX (n = 5-6 mice per group).…”
mentioning
confidence: 99%